Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Dec 16, 2021
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how the types of foods we eat might affect the risk of developing breast cancer. Researchers want to understand if certain diets, which can cause inflammation in the body, may influence the chances of getting breast-related conditions like atypical ductal hyperplasia or lobular carcinoma in situ. The goal is to find ways to identify people at higher risk and to improve strategies for preventing breast cancer by helping doctors make better recommendations about diet.
To participate in this study, you need to be at least 18 years old and have been seen at a high-risk clinic for breast cancer. This includes individuals with a family history of breast cancer or those who have had specific breast-related conditions. You should also be able to read and understand English and provide consent to let researchers follow your medical records during the study. If you join, you can expect to share information about your diet and health, which may help improve future breast cancer prevention efforts.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>= 18 years
- • Established in the high risk clinic at OSUCCC- James (includes patients with family history of breast cancer \[BC\], known genetic predisposition, personal history of known atypia/breast lobular carcinoma in situ \[LCIS\], or prior chest wall radiation)
- • Patients at high risk for BC established in the surgical oncology clinic at Stefanie Spielman Comprehensive Breast Center (SSCBC), with one of the following diagnoses: Atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), sclerosing adenosis (SA), or radial scars (RS)
- • Able to read and understand English
- • Able to provide informed consent
- • Must consent to continued follow-up of medical records during the study period
- Exclusion Criteria:
- • Prisoners
- • Not able to speak and understand English
- • Known personal history of ductal carcinoma in situ (DCIS) or Invasive BC
About Ohio State University Comprehensive Cancer Center
The Ohio State University Comprehensive Cancer Center (OSUCCC) is a leading institution dedicated to advancing cancer research, treatment, and education. As a National Cancer Institute-designated comprehensive cancer center, OSUCCC integrates cutting-edge research with clinical practice to develop innovative therapies and improve patient outcomes. With a collaborative approach that unites scientists and clinicians, OSUCCC focuses on personalized medicine, cancer prevention, and community outreach, striving to enhance the understanding of cancer biology and provide hope to patients through groundbreaking clinical trials and comprehensive care programs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Patients applied
Trial Officials
Sagar D Sardesai, MSPH, PhD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials